IDEAYA Biosciences, Inc. (IDYA)
Market Cap | 2.55B |
Revenue (ttm) | 15.50M |
Net Income (ttm) | -128.89M |
Shares Out | 75.69M |
EPS (ttm) | -2.01 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 841,906 |
Open | 35.80 |
Previous Close | 35.92 |
Day's Range | 33.38 - 36.09 |
52-Week Range | 20.90 - 47.74 |
Beta | 0.78 |
Analysts | Strong Buy |
Price Target | 49.80 (+47.69%) |
Earnings Date | Aug 8, 2024 |
About IDYA
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioa... [Read more]
Financial Performance
In 2023, IDYA's revenue was $23.39 million, a decrease of -54.08% compared to the previous year's $50.93 million. Losses were -$112.96 million, 92.6% more than in 2022.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for IDYA stock is "Strong Buy." The 12-month stock price forecast is $49.8, which is an increase of 47.69% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/z/m/press3-2501424.jpg)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , June 28, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap...
![](https://cdn.snapi.dev/images/v1/w/u/press6-2494583.jpg)
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer
First-Patient-In (FPI) for Phase 1 combination treatment with IDE397, IDEAYA's MAT2A inhibitor, and Trodelvy®, Gilead's Trop-2 directed antibody-drug conjugate (ADC) The global Phase 1 clinical trial ...
![](https://cdn.snapi.dev/images/v1/4/i/press12-2492279.jpg)
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors
Targeting IDE397 Phase 2 monotherapy expansion dose clinical data update in over ~15 evaluable MTAP lung and bladder cancer patients in H2 2024, including RECIST 1.1 clinical efficacy waterfall, swim-...
![](https://cdn.snapi.dev/images/v1/u/9/press4-2458423.jpg)
IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study
75% eye preservation rate (9 of 12 enucleation patients) ~67% (8 of 12 enucleation patients) observed greater than 30% tumor shrinkage and median tumor shrinkage of 47% by volume change after 6 months...
![](https://cdn.snapi.dev/images/v1/n/p/press3-2451033.jpg)
IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events
SOUTH SAN FRANCISCO, Calif. , May 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therape...
![](https://cdn.snapi.dev/images/v1/m/m/press19-2449287.jpg)
IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development
Over 18-years at leading life sciences and strategy consulting companies, including Revolution Medicines, Guardant Health, Onyx Pharmaceuticals, and McKinsey & Company SOUTH SAN FRANCISCO, Calif. , Ma...
![](https://cdn.snapi.dev/images/v1/p/h/press16-2446515.jpg)
IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma
~67% eye preservation rate (6 of 9 enucleation patients) with darovasertib monotherapy neoadjuvant uveal melanoma treatment Median tumor shrinkage (maximum volume change) of ~39% after 6 months Clinic...
![](https://cdn.snapi.dev/images/v1/z/z/press13-2413983.jpg)
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
ASCO 2024 oral presentation of darovasertib neoadjuvant UM Phase 2 investigator-sponsored trial on June 3rd, and targeting neoadjuvant UM update in over 30 patients from Phase 2 company-sponsored tria...
![](https://cdn.snapi.dev/images/v1/z/n/press9-2402077.jpg)
IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
SOUTH SAN FRANCISCO, Calif. , May 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeu...
![](https://cdn.snapi.dev/images/v1/o/u/press20-2388346.jpg)
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024, at 9:51 AM CDT The abstract summary will be available on Thursday, May 23, 2024 at ~5:00pm ET SOUTH SAN FRANCISCO, Calif. , April 24,...
![](https://cdn.snapi.dev/images/v1/9/a/press14-2382520.jpg)
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on AE profile and preliminary clinical efficacy observed, including multiple partial respon...
![](https://cdn.snapi.dev/images/v1/m/e/press4-2349329.jpg)
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
SOUTH SAN FRANCISCO, Calif. , April 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therap...
![](https://cdn.snapi.dev/images/v1/a/j/press10-2319407.jpg)
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therape...
![](https://cdn.snapi.dev/images/v1/9/q/press18-2305742.jpg)
IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events
SAN FRANCISCO , March 4, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announ...
![](https://cdn.snapi.dev/images/v1/8/3/press1-2282968.jpg)
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Targeting two independent Phase 2 clinical efficacy updates for darovasertib in neoadjuvant uveal melanoma (UM) in mid-2024, including from the Phase 2 IST and Phase 2 company-sponsored study Targetin...
![](https://cdn.snapi.dev/images/v1/g/u/press15-2254849.jpg)
IDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events
SOUTH SAN FRANCISCO, Calif. , Feb. 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therape...
![](https://cdn.snapi.dev/images/v1/l/z/press18-2219372.jpg)
IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance
SOUTH SAN FRANCISCO, Calif. , Jan. 7, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therape...
![](https://cdn.snapi.dev/images/v1/b/y/press1-2183206.jpg)
IDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event
SOUTH SAN FRANCISCO, Calif. , Dec. 5, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therape...
![](https://cdn.snapi.dev/images/v1/r/m/press15-2181430.jpg)
IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer
Entered into Clinical Study Collaboration and Supply Agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with sacituzumab-govitecan-hziy ("Trodelvy") Gilead's Trop-2 dir...
![](https://cdn.snapi.dev/images/v1/z/f/conf19-2181104.jpg)
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023
SOUTH SAN FRANCISCO, Calif. , Dec. 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therape...
![](https://cdn.snapi.dev/images/v1/q/x/press4-2143354.jpg)
IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
Strong balance sheet of $511.1 million of cash, cash equivalents and marketable securities as of September 30, 2023, supplemented by $134.7 million estimated net proceeds from subsequent follow-on fin...
![](https://cdn.snapi.dev/images/v1/i/i/press10-2132236.jpg)
IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therape...
![](https://cdn.snapi.dev/images/v1/2/d/press3-2126564.jpg)
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. , Oct. 27, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its underwritten public offering of 5,797,872 shares of its common sto...
![](https://cdn.snapi.dev/images/v1/c/w/press1-2118987.jpg)
IDEAYA Announces Pricing of Public Offering
SOUTH SAN FRANCISCO, Calif. , Oct. 24, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warran...
![](https://cdn.snapi.dev/images/v1/c/h/press16-2118438.jpg)
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif. , Oct. 24, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $125.0 million of shares of its common stock ...